STOCKHOLDERS' EQUITY |
3 Months Ended |
|---|---|
Mar. 31, 2024 | |
| STOCKHOLDERS' EQUITY | |
| STOCKHOLDERS' EQUITY |
NOTE 4 – STOCKHOLDERS' EQUITY
Equity Sales
During the quarter ended March 31, 2024, the Company sold common stock in 20 private unregistered transactions resulting in total proceeds of $1,103,326 and the issuance of 407,299 shares of common stock. Included in the totals are 56,666 shares of common stock sold to related parties for proceeds of $130,782. The Company had no sales of common stock in the quarter ended March 31, 2023.
Equity Compensation
For the quarter ended March 31, 2024, the Company recognized expense of $112,104 for equity compensation to members of the Board of Directors and certain employees. The total expense amount was related to equity awards from prior periods as no new equity awards were granted in the quarter. $34,648 of the total expense for the quarter was related to R&D and the remaining $77,456 was for G&A.
For the quarter ended March 31, 2023, the Company expensed $242,102 for equity compensation to members of the Board of Directors and certain employees. The total expense amount was related to equity awards from prior periods as no new equity awards were granted in the quarter. $77,383 of the total expense for the quarter was related to R&D and the remaining $164,719 was for G&A. |